BioNTech is a German biotechnology company known for its focus on developing and manufacturing immunotherapies and vaccines, particularly those based on messenger RNA (mRNA) technology. Founded in 2008, BioNTech gained international prominence for its role in developing one of the first COVID-19 vaccines in collaboration with Pfizer. The company’s approach leverages cutting-edge scientific innovations to create targeted treatments for various diseases, including cancer and infectious diseases. BioNTech’s mRNA technology works by using genetic instructions to prompt the body’s cells to produce proteins that can trigger an immune response. This method represents a shift in vaccine development and has potential applications beyond infectious diseases, including personalized medicine for cancer treatment.
BioNTech faces challenges as COVID-19 vaccine revenue declines, with earnings per share dropping from €1.90 to €1.08. To combat financial downturn, BioNTech is investing heavily in mRNA-based cancer therapies, leading…